MedTrace Logo

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

NCT06242392 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2024-02-05

No results posted yet for this study

Summary

Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.

Conditions

  • Ovarian Neoplasms

Interventions

GENETIC

homologous recombination deficiency

Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.

Sponsors & Collaborators

  • Fujian Provincial Hospital

    collaborator OTHER

  • Fujian Cancer Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2026-05-01
Completion
2026-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06242392 on ClinicalTrials.gov